Premium
Tumor‐infiltrating tryptase + mast cells predict unfavorable clinical outcome in solid tumors
Author(s) -
Hu Guoming,
Wang Shimin,
Cheng Pu
Publication year - 2017
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.31099
Subject(s) - tryptase , medicine , mast cell , pathology , infiltration (hvac) , colorectal cancer , hepatocellular carcinoma , cancer research , lymph node , metastasis , oncology , cancer , immunology , physics , thermodynamics
The prognostic role of tumor‐infiltrating tryptase + mast cells in human solid tumors remains controversial. Herein, we conducted a meta‐analysis including 28 published studies with 4224 patients identified from PubMed and EBSCO to assess the prognostic impact of tumor‐infiltrating tryptase + mast cells in human solid tumors. We found that tryptase + mast cell infiltration significantly decreased overall survival (OS) and disease‐free survival (DFS) in all types of solid tumors. In stratified analyses, tryptase + mast cell infiltration was significantly associated with worse OS in non‐small cell lung cancer, hepatocellular carcinoma and 5‐year survival in colorectal cancer. And these cells were inversely associated with DFS in hepatocellular and colorectal cancer. In addition, high density of intratumoral tryptase + mast cells significantly correlated with lymph node metastasis of solid tumor. In conclusion, Tryptase + mast cell infiltration leads to an unfavorable clinical outcome in solid tumors, implicating that it is a valuable biomarker for prognostic prediction for human solid malignances and targeting it may have a potential for effective treatment.